Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Torregrosa-Maicas, Maria Dolores
- dc.contributor.author Barco Berrón, Sonia del
- dc.contributor.author Cotes Sanchís, Almudena
- dc.contributor.author Lema Roso, L.
- dc.contributor.author Servitja Tormo, Sonia
- dc.contributor.author Gironés i Sarrió, Regina
- dc.date.accessioned 2022-08-30T09:32:05Z
- dc.date.available 2022-08-30T09:32:05Z
- dc.date.issued 2022
- dc.description.abstract Most patients diagnosed with luminal metastatic breast cancer (MBC) who are seen in oncology consultations are elderly. MBC in elderly patients is characterized by a higher percentage of hormone receptor (HR) expression and a lower expression of human epidermal growth factor receptor 2 (HER2). The decision regarding which treatment to administer to these patients is complex due to the lack of solid evidence to support the decision-making process. The objective of this paper is to review the scientific evidence on the treatment of elderly patients with luminal MBC. For this purpose, the Oncogeriatrics Section of the Spanish Society of Medical Oncology (SEOM), the Spanish Breast Cancer Research Group (GEICAM) and the SOLTI Group appointed a group of experts who have worked together to establish consensus recommendations to optimize the treatment of this population. It was concluded that the chronological age of the patient alone should not guide therapeutic decisions and that a Comprehensive Geriatric Assessment (CGA) should be performed whenever possible before establishing treatment. Treatment selection for the elderly population should consider the patient's baseline status, the expected benefit and toxicity of each treatment, and the impact of treatment toxicity on the patient's quality of life and functionality.
- dc.format.mimetype application/pdf
- dc.identifier.citation Torregrosa-Maicas MD, Del Barco-Berrón S, Cotes-Sanchís A, Lema-Roso L, Servitja-Tormo S, Gironés-Sarrió R. Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. Clin Transl Oncol. 2022 Jun;24(6):1033-46. DOI: 10.1007/s12094-021-02766-8
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-021-02766-8
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/53937
- dc.language.iso eng
- dc.publisher Springer
- dc.relation.ispartof Clin Transl Oncol. 2022 Jun;24(6):1033-46
- dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Cyclin inhibitors
- dc.subject.keyword Geriatrics
- dc.subject.keyword Hormone therapy
- dc.subject.keyword PARP inhibitors
- dc.subject.keyword PI3K inhibitors
- dc.subject.keyword mTOR inhibitors
- dc.title Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion